<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39397784</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.</ArticleTitle><Pagination><StartPage>2410574</StartPage><MedlinePgn>2410574</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2410574</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2024.2410574</ELocationID><Abstract><AbstractText>Next-generation COVID-19 vaccines are being developed to expand the breadth of coverage against existing and future variants and to extend the duration of protection. Prime-2-CoV_Beta is an orf virus (ORFV) based multi-antigen COVID-19 vaccine that co-expresses Spike (S) and Nucleocapsid (N) antigens. The safety and immunogenicity of Prime-2-CoV_Beta is investigated in a phase 1 first-in-human (FIH) dose-finding trial (ORFEUS study, ClinicalTrials.gov: NCT05367843). Participants of two age groups (18-55 and 65-85 years) who previously completed at least two doses of mRNA vaccines were enrolled and sequentially assigned to different dose groups to receive one intramuscular dose of 3 × 10<sup>5</sup>, 3 × 10<sup>6</sup>, 1.5 × 10<sup>7</sup>, or 3 × 10<sup>7</sup> plaque-forming units (PFU) of Prime-2-CoV_Beta on day 1 and a second dose on day 29. Here, we report safety and immunogenicity data collected up to 6 months after the first study vaccination. Prime-2-CoV_Beta is safe and well tolerated and elicits immune responses at higher dose levels in participants aged 18-55. A single dose of 3 × 10<sup>7</sup> PFU boosted binding and cross-neutralizing antibody responses that are maintained through 6 months after the first booster vaccination. Polyfunctional S-specific CD4+ and CD8+ T cell responses are observed after vaccination. No pre-existing or vaccine-induced neutralizing anti-vector antibodies are detected. Our findings highlight the potential of the ORFV vector as a safe platform for future vaccine design, which provides the ability to deliver multiple antigens and allows for repeat immunization.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klinkardt</LastName><ForeName>Ute</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Speransa Therapeutics, TowerOne (Spaces), Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schunk</LastName><ForeName>Mirjam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ervin</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>AMR - Center for Pharmaceutical Research, Kansas City, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medizinische Hochschule Hannover (MHH), Center for Clinical Trials (ZKS) - Early Clinical Trial Unit (ECTU), Hanover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugimoto</LastName><ForeName>Danny</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cedar Crosse Research Cente, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rankin</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Accel Research Sites (ARS) - Corporate Office, DeLand, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amann</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monti</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VisMederi Srl, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kutschenko</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medizinische Hochschule Hannover (MHH), Center for Clinical Trials (ZKS) - Early Clinical Trial Unit (ECTU), Hanover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schumacher</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medizinische Hochschule Hannover (MHH), Center for Clinical Trials (ZKS) - Early Clinical Trial Unit (ECTU), Hanover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeder</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heikkila</LastName><ForeName>Nelli</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didierlaurent</LastName><ForeName>Arnaud M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Center of Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Sylvia E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Speransa Therapeutics, TowerOne (Spaces), Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derouazi</LastName><ForeName>Madiha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Speransa Therapeutics, TowerOne (Spaces), Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05367843</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009923" MajorTopicYN="N">Orf virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ORF virus-vector</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword><Keyword MajorTopicYN="N">booster vaccine</Keyword><Keyword MajorTopicYN="N">first-in-human trial</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>Rald Amann holds ownership interest in Prime Vector Technologies GmbH, a company involved in the development of ORFV-based vaccines. Additionally, Ralf Amann is an inventor of patents related to ORFV, including a patent application of Prime-2-CoV. Ute Klinkhardt, Sylvia E. Schwarz and Madiha Derouazi were employed by Speransa Therapeutics GmbH. Arnaud M. Didierlaurent declared personal consulting fees for participation to scientific advisory boards for Speransa, Bioaster and Sanofi Pasteur, and participation on a Data Safety Monitoring Board for AMC Biosciences, all unrelated to the present work and is the chairman of the WHO Technical advisory group for Emergency use listing of COVID-19 vaccines..</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39397784</ArticleId><ArticleId IdType="pmc">PMC11485980</ArticleId><ArticleId IdType="doi">10.1080/21645515.2024.2410574</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Krammer F, Ellebedy AH.. Variant-adapted COVID-19 booster vaccines. Science. 2023;382(6667):157–14. doi:10.1126/science.adh2712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adh2712</ArticleId><ArticleId IdType="pubmed">37824671</ArticleId></ArticleIdList></Reference><Reference><Citation>Amann R, Rohde J, Wulle U, Conlee D, Raue R, Martinon O, Rziha H-J.. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein. J Virol. 2013;87(3):1618–1630. doi:10.1128/JVI.02470-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02470-12</ArticleId><ArticleId IdType="pmc">PMC3554190</ArticleId><ArticleId IdType="pubmed">23175365</ArticleId></ArticleIdList></Reference><Reference><Citation>Reguzova A, Ghosh M, Müller M, Rziha HJ, Amann R. Orf virus-based vaccine vector D1701-V induces strong CD8+ T cell response against the transgene but not against ORFV-Derived epitopes. Vaccines (Basel). 2020;8(2):8. doi:10.3390/vaccines8020295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8020295</ArticleId><ArticleId IdType="pmc">PMC7349966</ArticleId><ArticleId IdType="pubmed">32531997</ArticleId></ArticleIdList></Reference><Reference><Citation>Reguzova A, Fischer N, Müller M, Salomon F, Jaenisch T, Amann R. A novel orf virus D1701-VrV-based dengue virus (DENV) vaccine candidate expressing HLA-Specific T cell epitopes: a proof-of-concept study. Biomedicines. 2021;9(12):1862. doi:10.3390/biomedicines9121862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9121862</ArticleId><ArticleId IdType="pmc">PMC8698572</ArticleId><ArticleId IdType="pubmed">34944678</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn JY, Lee J, Suh YS, Song YG, Choi YJ, Lee KH, Seo SH, Song M, Oh J-W, Kim M, et al. Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. Lancet Microbe. 2022;3(3):173–183. doi:10.1016/S2666-5247(21)00358-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00358-X</ArticleId><ArticleId IdType="pmc">PMC8824525</ArticleId><ArticleId IdType="pubmed">35156068</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieling P, King T, Wong R, Nguyen A, Wnuk K, Gabitzsch E, Rice A, Adisetiyo H, Hermreck M, Verma M, Zakin L. Prime hAd5 spike + nucleocapsid vaccination induces Ten-fold increases in mean T-Cell responses in phase 1 subjects that are sustained against spike variants. medRxiv 2021:2021.04.05.21254940.</Citation></Reference><Reference><Citation>Chiuppesi F, Zaia JA, Frankel PH, Stan R, Drake J, Williams B, Acosta AM, Francis K, Taplitz RA, Dickter JK, et al. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. Lancet Microbe. 2022;3(4):252–264. doi:10.1016/S2666-5247(22)00027-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00027-1</ArticleId><ArticleId IdType="pmc">PMC8906816</ArticleId><ArticleId IdType="pubmed">35287430</ArticleId></ArticleIdList></Reference><Reference><Citation>Reguzova A, Sigle M, Pagallies F, Salomon F, Rziha HJ, Bittner-Schrader Z, Verstrepen B, Böszörményi K, Verschoor E, Elbers K, et al. A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challenge. Res Sq [preprint]. 2023. doi:10.21203/rs.3.rs-2832501/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-2832501/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Burri DJ, Renz L, Mueller M, Pagallies F, Klinkhardt U, Amann R, Derouazi M. Novel multi-antigen orf-virus-derived vaccine elicits protective anti-SARS-CoV-2 response in monovalent and bivalent formats. Vaccines. 2024;12(5):490. doi:10.3390/vaccines12050490.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12050490</ArticleId><ArticleId IdType="pmc">PMC11126134</ArticleId><ArticleId IdType="pubmed">38793740</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, et al. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022;22(12):1703–1715. doi:10.1016/S1473-3099(22)00506-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00506-0</ArticleId><ArticleId IdType="pmc">PMC9639796</ArticleId><ArticleId IdType="pubmed">36113538</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallory RM, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, McFall H, Robinson M, Plested JS, Zhu M, et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2022;22(11):1565–1576. doi:10.1016/S1473-3099(22)00420-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00420-0</ArticleId><ArticleId IdType="pmc">PMC9365313</ArticleId><ArticleId IdType="pubmed">35963274</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22(8):1131–1141. doi:10.1016/S1473-3099(22)00271-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00271-7</ArticleId><ArticleId IdType="pmc">PMC9084623</ArticleId><ArticleId IdType="pubmed">35550261</ArticleId></ArticleIdList></Reference><Reference><Citation>Parés-Badell O, Zules-Oña R, Armadans L, Pinós L, Borrás-Bermejo B, Otero S, Rodrigo-Pendás JÁ, Vivet-Escalé M, Cossio-Gil Y, Agustí A, et al. Reactogenicity to the mRNA-1273 booster according to previous mRNA COVID-19 vaccination. Vaccines (Basel). 2022;10(8):10. doi:10.3390/vaccines10081217.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10081217</ArticleId><ArticleId IdType="pmc">PMC9414494</ArticleId><ArticleId IdType="pubmed">36016105</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, et al. Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCoV-19) covid-19 vaccine. N Engl J Med. 2021;385(25):2348–2360. doi:10.1056/NEJMoa2105290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105290</ArticleId><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, et al. A bivalent omicron-containing booster vaccine against Covid-19. N Engl J Med. 2022;387(14):1279–1291. doi:10.1056/NEJMoa2208343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2208343</ArticleId><ArticleId IdType="pmc">PMC9511634</ArticleId><ArticleId IdType="pubmed">36112399</ArticleId></ArticleIdList></Reference><Reference><Citation>Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, et al. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat Med. 2023;29(9):2334–2346. doi:10.1038/s41591-023-02503-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02503-4</ArticleId><ArticleId IdType="pmc">PMC10504073</ArticleId><ArticleId IdType="pubmed">37640860</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, Xie X, Shi P. Low neutralization of SARS-CoV-2 omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2023;29(2):344–347. doi:10.1038/s41591-022-02162-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02162-x</ArticleId><ArticleId IdType="pubmed">36473500</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards NE, Keshavarz B, Workman LJ, Nelson MR, Platts-Mills TAE, Wilson JM. Comparison of SARS-CoV-2 antibody response by age among recipients of the BNT162b2 vs the mRNA-1273 vaccine. Vol. 4. JAMA Netw Open; 2021. p. e2124331. doi:10.1001/jamanetworkopen.2021.24331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.24331</ArticleId><ArticleId IdType="pmc">PMC8414189</ArticleId><ArticleId IdType="pubmed">34473262</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockman MA, Mwimanzi F, Lapointe HR, Sang Y, Agafitei O, Cheung PK, Ennis S, Ng K, Basra S, Lim LY, et al. Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults. J Infect Dis. 2022;225(7):1129–1140. doi:10.1093/infdis/jiab592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab592</ArticleId><ArticleId IdType="pmc">PMC8689804</ArticleId><ArticleId IdType="pubmed">34888688</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S, Whatley JL, Eder F, Essink B, Khetan S, Bradley P, Brosz A, McGhee N, Tomassini JE, Chen X, et al. Original SARS-CoV-2 monovalent and omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results. Nat Med. 2023;29(9):2325–2333. doi:10.1038/s41591-023-02517-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02517-y</ArticleId><ArticleId IdType="pmc">PMC10504066</ArticleId><ArticleId IdType="pubmed">37653342</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee VaRBPA . Advisory committee meeting, vaccines and related biological products advisory committee June 28, 2022. 2022.</Citation></Reference><Reference><Citation>Favresse J, Gillot C, Bayart JL, David C, Simon G, Wauthier L, Closset M, Dogné J-M, Douxfils J. Vaccine-induced binding and neutralizing antibodies against omicron 6 months after a homologous BNT162b2 booster. J Med Virol. 2023;95(1):e28164. doi:10.1002/jmv.28164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28164</ArticleId><ArticleId IdType="pmc">PMC9538323</ArticleId><ArticleId IdType="pubmed">36131356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornsby H, Nicols AR, Longet S, Liu C, Tomic A, Angyal A, Kronsteiner B, Tyerman JK, Tipton T, Zhang P, et al. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history. Nat Commun. 2023;14(1):5065. doi:10.1038/s41467-023-40592-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40592-4</ArticleId><ArticleId IdType="pmc">PMC10442364</ArticleId><ArticleId IdType="pubmed">37604803</ArticleId></ArticleIdList></Reference><Reference><Citation>Markewitz R, Pauli D, Dargvainiene J, Steinhagen K, Engel S, Herbst V, Zapf D, Krüger C, Sharifzadeh S, Schomburg B, et al. B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose. Clin Microbiol Infect. 2022;28(7):1024.1–.6. doi:10.1016/j.cmi.2022.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.02.028</ArticleId><ArticleId IdType="pmc">PMC8897957</ArticleId><ArticleId IdType="pubmed">35259531</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannawi S, Saifeldin L, Abuquta A, Alamadi A, Mahmoud SA, Hassan A, Liu D, Yan L, Xie L. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial. EBioMedicine. 2023;87:104386. doi:10.1016/j.ebiom.2022.104386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104386</ArticleId><ArticleId IdType="pmc">PMC9720098</ArticleId><ArticleId IdType="pubmed">36470077</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, Singh J, Shaman H, Singh B, Anantharaj A, Sharanabasava P, Pandey R, Lodha R, Pandey AK, Medigeshi GR, et al. Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination. Nat Commun. 2022;13(1):3451. doi:10.1038/s41467-022-31170-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31170-1</ArticleId><ArticleId IdType="pmc">PMC9199457</ArticleId><ArticleId IdType="pubmed">35705548</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, Wang T, Yan F, Yang S, Xia X, et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023;8(1):149. doi:10.1038/s41392-023-01408-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01408-5</ArticleId><ArticleId IdType="pmc">PMC10081433</ArticleId><ArticleId IdType="pubmed">37029123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Kim C, Lee JA, Lee SJ, Lee KH, Kim JH, Ahn JY, Jeong SJ, Ku NS, Yeom J-S, et al. Immunogenicity differences of the ChAdOx1 nCoV-19 vaccine according to pre-existing adenovirus immunity. Vaccines (Basel). 2023;11(4):11. doi:10.3390/vaccines11040784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11040784</ArticleId><ArticleId IdType="pmc">PMC10145356</ArticleId><ArticleId IdType="pubmed">37112696</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>